Rating impairment and disability in Parkinson's disease: Evaluation of the unified Parkinson's disease rating scale
Identifieur interne : 005B07 ( Main/Exploration ); précédent : 005B06; suivant : 005B08Rating impairment and disability in Parkinson's disease: Evaluation of the unified Parkinson's disease rating scale
Auteurs : van Hilten [Pays-Bas] ; A. D. Van Der Zwan [Pays-Bas] ; A. H. Zwinderman [Pays-Bas] ; R. A. C. Roos [Pays-Bas]Source :
- Movement Disorders [ 0885-3185 ] ; 1994.
English descriptors
- KwdEn :
- Activities of Daily Living (classification), Adult, Aged, Aged, 80 and over, Antiparkinson Agents (adverse effects), Antiparkinson Agents (therapeutic use), Disability Evaluation, Female, Humans, Male, Middle Aged, Neurologic Examination (classification), Neurologic Examination (drug effects), Neurologic Examination (statistics & numerical data), Parkinson Disease (classification), Parkinson Disease (diagnosis), Parkinson Disease (drug therapy), Reproducibility of Results, Unified Parkinson's Disease Rating Scale.
- MESH :
- chemical , adverse effects : Antiparkinson Agents.
- classification : Activities of Daily Living, Neurologic Examination, Parkinson Disease.
- diagnosis : Parkinson Disease.
- drug effects : Neurologic Examination.
- drug therapy : Parkinson Disease.
- statistics & numerical data : Neurologic Examination.
- chemical , therapeutic use : Antiparkinson Agents.
- Adult, Aged, Aged, 80 and over, Disability Evaluation, Female, Humans, Male, Middle Aged, Reproducibility of Results.
Abstract
Although the Unified Parkinson's Disease Rating Scale (UPDRS) is widely used to monitor disease progression and drug efficacy, no attempts have been made to evaluate its scientific and clinical quality. Poor clinical sensibility of items in the activities of daily living (ADL) section and redundancy of items in the motor examination (ME) section prompted us to determine if the number of items in these sections could be reduced to a smaller, equally sensitive set that would describe the data as relibly as did the original set of items. Therefore, we assessed 111 patients with idiopathic Parkinson's disease on the UPDRS and Hoehn and Yahr staging scales. Our results show that the ADL (13 items) and ME (14 items) sections can be reduced to 8 items each without loss of reliability or validity. Our report is preliminary and needs validation.
Url:
DOI: 10.1002/mds.870090113
Affiliations:
Links toward previous steps (curation, corpus...)
- to stream Istex, to step Corpus: 002F72
- to stream Istex, to step Curation: 002F72
- to stream Istex, to step Checkpoint: 003E42
- to stream PubMed, to step Corpus: 004B49
- to stream PubMed, to step Curation: 004B49
- to stream PubMed, to step Checkpoint: 004A76
- to stream Ncbi, to step Merge: 004899
- to stream Ncbi, to step Curation: 004899
- to stream Ncbi, to step Checkpoint: 004899
- to stream Main, to step Merge: 008C98
- to stream Main, to step Curation: 005B07
Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Rating impairment and disability in Parkinson's disease: Evaluation of the unified Parkinson's disease rating scale</title><author><name sortKey="Van Hilten" sort="Van Hilten" uniqKey="Van Hilten" last="Van Hilten">van Hilten</name></author><author><name sortKey="Van Der Zwan, A D" sort="Van Der Zwan, A D" uniqKey="Van Der Zwan A" first="A. D." last="Van Der Zwan">A. D. Van Der Zwan</name></author><author><name sortKey="Zwinderman, A H" sort="Zwinderman, A H" uniqKey="Zwinderman A" first="A. H." last="Zwinderman">A. H. Zwinderman</name></author><author><name sortKey="Roos, R A C" sort="Roos, R A C" uniqKey="Roos R" first="R. A. C." last="Roos">R. A. C. Roos</name></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:28566BB84C0007293C95949412F44D26C7D4AF96</idno><date when="1994" year="1994">1994</date><idno type="doi">10.1002/mds.870090113</idno><idno type="url">https://api.istex.fr/document/28566BB84C0007293C95949412F44D26C7D4AF96/fulltext/pdf</idno><idno type="wicri:Area/Istex/Corpus">002F72</idno><idno type="wicri:Area/Istex/Curation">002F72</idno><idno type="wicri:Area/Istex/Checkpoint">003E42</idno><idno type="wicri:doubleKey">0885-3185:1994:Van Hilten:rating:impairment:and</idno><idno type="wicri:source">PubMed</idno><idno type="RBID">pubmed:8139609</idno><idno type="wicri:Area/PubMed/Corpus">004B49</idno><idno type="wicri:Area/PubMed/Curation">004B49</idno><idno type="wicri:Area/PubMed/Checkpoint">004A76</idno><idno type="wicri:Area/Ncbi/Merge">004899</idno><idno type="wicri:Area/Ncbi/Curation">004899</idno><idno type="wicri:Area/Ncbi/Checkpoint">004899</idno><idno type="wicri:doubleKey">0885-3185:1994:Van Hilten J:rating:impairment:and</idno><idno type="wicri:Area/Main/Merge">008C98</idno><idno type="wicri:Area/Main/Curation">005B07</idno><idno type="wicri:Area/Main/Exploration">005B07</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Rating impairment and disability in Parkinson's disease: Evaluation of the unified Parkinson's disease rating scale</title><author><name sortKey="Van Hilten" sort="Van Hilten" uniqKey="Van Hilten" last="Van Hilten">van Hilten</name><affiliation wicri:level="1"><country xml:lang="fr">Pays-Bas</country><wicri:regionArea>Department of Neurology, Academic Hospital</wicri:regionArea><wicri:noRegion>Academic Hospital</wicri:noRegion></affiliation></author><author><name sortKey="Van Der Zwan, A D" sort="Van Der Zwan, A D" uniqKey="Van Der Zwan A" first="A. D." last="Van Der Zwan">A. D. Van Der Zwan</name><affiliation wicri:level="1"><country xml:lang="fr">Pays-Bas</country><wicri:regionArea>Department of Neurology, Academic Hospital</wicri:regionArea><wicri:noRegion>Academic Hospital</wicri:noRegion></affiliation></author><author><name sortKey="Zwinderman, A H" sort="Zwinderman, A H" uniqKey="Zwinderman A" first="A. H." last="Zwinderman">A. H. Zwinderman</name><affiliation wicri:level="3"><country xml:lang="fr">Pays-Bas</country><wicri:regionArea>Department of Medical Statistics, State University of Leiden, Leiden</wicri:regionArea><placeName><settlement type="city">Leyde</settlement><region nuts="2" type="province">Hollande-Méridionale</region></placeName></affiliation></author><author><name sortKey="Roos, R A C" sort="Roos, R A C" uniqKey="Roos R" first="R. A. C." last="Roos">R. A. C. Roos</name><affiliation wicri:level="1"><country xml:lang="fr">Pays-Bas</country><wicri:regionArea>Department of Neurology, Academic Hospital</wicri:regionArea><wicri:noRegion>Academic Hospital</wicri:noRegion></affiliation></author></analytic><monogr></monogr><series><title level="j">Movement Disorders</title><title level="j" type="abbrev">Mov. Disord.</title><idno type="ISSN">0885-3185</idno><idno type="eISSN">1531-8257</idno><imprint><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><pubPlace>Hoboken</pubPlace><date type="published" when="1994">1994</date><biblScope unit="vol">9</biblScope><biblScope unit="issue">1</biblScope><biblScope unit="page" from="84">84</biblScope><biblScope unit="page" to="88">88</biblScope></imprint><idno type="ISSN">0885-3185</idno></series><idno type="istex">28566BB84C0007293C95949412F44D26C7D4AF96</idno><idno type="DOI">10.1002/mds.870090113</idno><idno type="ArticleID">MDS870090113</idno></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0885-3185</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Activities of Daily Living (classification)</term><term>Adult</term><term>Aged</term><term>Aged, 80 and over</term><term>Antiparkinson Agents (adverse effects)</term><term>Antiparkinson Agents (therapeutic use)</term><term>Disability Evaluation</term><term>Female</term><term>Humans</term><term>Male</term><term>Middle Aged</term><term>Neurologic Examination (classification)</term><term>Neurologic Examination (drug effects)</term><term>Neurologic Examination (statistics & numerical data)</term><term>Parkinson Disease (classification)</term><term>Parkinson Disease (diagnosis)</term><term>Parkinson Disease (drug therapy)</term><term>Reproducibility of Results</term><term>Unified Parkinson's Disease Rating Scale</term></keywords><keywords scheme="MESH" type="chemical" qualifier="adverse effects" xml:lang="en"><term>Antiparkinson Agents</term></keywords><keywords scheme="MESH" qualifier="classification" xml:lang="en"><term>Activities of Daily Living</term><term>Neurologic Examination</term><term>Parkinson Disease</term></keywords><keywords scheme="MESH" qualifier="diagnosis" xml:lang="en"><term>Parkinson Disease</term></keywords><keywords scheme="MESH" qualifier="drug effects" xml:lang="en"><term>Neurologic Examination</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Parkinson Disease</term></keywords><keywords scheme="MESH" qualifier="statistics & numerical data" xml:lang="en"><term>Neurologic Examination</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Antiparkinson Agents</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Adult</term><term>Aged</term><term>Aged, 80 and over</term><term>Disability Evaluation</term><term>Female</term><term>Humans</term><term>Male</term><term>Middle Aged</term><term>Reproducibility of Results</term></keywords></textClass><langUsage><language ident="en">en</language></langUsage></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Although the Unified Parkinson's Disease Rating Scale (UPDRS) is widely used to monitor disease progression and drug efficacy, no attempts have been made to evaluate its scientific and clinical quality. Poor clinical sensibility of items in the activities of daily living (ADL) section and redundancy of items in the motor examination (ME) section prompted us to determine if the number of items in these sections could be reduced to a smaller, equally sensitive set that would describe the data as relibly as did the original set of items. Therefore, we assessed 111 patients with idiopathic Parkinson's disease on the UPDRS and Hoehn and Yahr staging scales. Our results show that the ADL (13 items) and ME (14 items) sections can be reduced to 8 items each without loss of reliability or validity. Our report is preliminary and needs validation.</div></front></TEI><affiliations><list><country><li>Pays-Bas</li></country><region><li>Hollande-Méridionale</li></region><settlement><li>Leyde</li></settlement></list><tree><country name="Pays-Bas"><noRegion><name sortKey="Van Hilten" sort="Van Hilten" uniqKey="Van Hilten" last="Van Hilten">van Hilten</name></noRegion><name sortKey="Roos, R A C" sort="Roos, R A C" uniqKey="Roos R" first="R. A. C." last="Roos">R. A. C. Roos</name><name sortKey="Van Der Zwan, A D" sort="Van Der Zwan, A D" uniqKey="Van Der Zwan A" first="A. D." last="Van Der Zwan">A. D. Van Der Zwan</name><name sortKey="Zwinderman, A H" sort="Zwinderman, A H" uniqKey="Zwinderman A" first="A. H." last="Zwinderman">A. H. Zwinderman</name></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 005B07 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 005B07 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Santé
|area= MovDisordV3
|flux= Main
|étape= Exploration
|type= RBID
|clé= ISTEX:28566BB84C0007293C95949412F44D26C7D4AF96
|texte= Rating impairment and disability in Parkinson's disease: Evaluation of the unified Parkinson's disease rating scale
}}
| This area was generated with Dilib version V0.6.23. |  |